.August 22, 2024 03:10:02 AM

PROCEPT BioRobotics, known by its NASDAQ ticker symbol PRCT, has achieved a breakthrough with the FDA clearance of its HYDROS™ Robotic System. This AI-powered platform enhances Aquablation® Therapy, improving efficiency and accuracy in treatment plans.

Following the FDA clearance, PROCEPT BioRobotics’ stock price surged to $83.44, a 28.36% increase. The company’s market capitalization now stands at approximately $4.33 billion, indicating strong market interest and financial stability.

The stock’s performance, reaching a year-high of $85.81, reflects investor confidence in PROCEPT BioRobotics’ future. The increased trading volume of 5,115,454 shares further demonstrates market interest in the company’s growth potential.